Amylin Pharmaceuticals and Takeda Pharmaceutical Company have entered a worldwide agreement to co-develop and commercialise pharmaceutical products for the treatment of obesity and related symptoms.

The agreement includes the development of Amylin products in the second phase of development for the treatment of obesity, such as pramlintide/metreleptin and davalintide. It also includes additional compounds from each company’s obesity research programmes.

The Californian biopharmaceutical company Amylin will receive a one-off payment of $75m from the Japanese research company Takeda, and will receive additional payments depending on certain development, commercialisation and sales-based targets that could reach as much as $1bn.